Abstract | BACKGROUND: METHODS: The patient underwent clinical and blood examinations and whole-body magnetic resonance imaging to assess tumor sizes. Lipoma cells of the patient were incubated with inhibitors of the phosphoinositide-3-kinase (PI3K)/AKT/mTOR signaling pathway to analyze the effects on proliferation, adipocyte differentiation, and survival in vitro. RESULTS:
Sirolimus treatment improved somatic growth and reduced thymus volume. These effects diminished over the treatment period of 19 mo. Sirolimus decreased lipoma cell proliferation and adipocyte differentiation in vitro but did not cause apoptosis. PI3K and AKT inhibitors induced apoptosis significantly. CONCLUSION:
Sirolimus treatment led to an improvement of the patient's clinical status and a transient reduction of the thymus. Our in vitro findings point to PI3K and AKT inhibitors as potential treatment options for patients with severe forms of PHTS.
|
Authors | Gordian L Schmid, Franziska Kässner, Holm H Uhlig, Antje Körner, Jürgen Kratzsch, Norman Händel, Fred-P Zepp, Frank Kowalzik, Andreas Laner, Sven Starke, Franziska K Wilhelm, Susanne Schuster, Adrian Viehweger, Wolfgang Hirsch, Wieland Kiess, Antje Garten |
Journal | Pediatric research
(Pediatr Res)
Vol. 75
Issue 4
Pg. 527-34
(Apr 2014)
ISSN: 1530-0447 [Electronic] United States |
PMID | 24366516
(Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- PTEN Phosphohydrolase
- PTEN protein, human
- Sirolimus
|
Topics |
- Child, Preschool
- Hamartoma Syndrome, Multiple
(drug therapy, genetics)
- Humans
- In Vitro Techniques
- Infant
- Infant, Newborn
- PTEN Phosphohydrolase
(genetics)
- Sirolimus
(therapeutic use)
|